Intellia Therapeutics (NTLA) stock is soaring 7.70% in pre-market trading on Monday, following Evercore ISI analyst Liisa Bayko's reiteration of a Buy rating on the company. The analyst maintained a price target of $48.00 for the stock, signaling confidence in the biotech firm's potential.
The positive analyst sentiment appears to be driving investor optimism, contributing to the significant pre-market surge. Evercore ISI's maintained Buy rating suggests that the firm believes Intellia Therapeutics has strong growth prospects and may be undervalued at its current price levels.
As the market opens, investors will be watching closely to see if this pre-market momentum carries through the regular trading session. The sustained bullish outlook from a respected analyst could potentially attract more buyers and further boost the stock's performance. However, as always, investors should conduct their own research and consider multiple factors before making investment decisions.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.